{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:01:25Z","timestamp":1769695285593,"version":"3.49.0"},"reference-count":99,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The interleukin (IL)-17 family encompasses six structurally related pro-inflammatory cystine knot proteins, designated as IL-17A to IL-17F. Over the last decades, evidence has pointed to its role as a critical player in the development of inflammatory diseases such as psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). More specifically, IL-17A and IL-17F are overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest their involvement in promoting inflammation and tissue damage in axSpA and PsA. Bimekizumab is a monoclonal antibody targeting both IL-17A and IL-17F, playing an important role in the treatment of these diseases. This review details the implications of bimekizumab in the therapeutic armamentarium of axSpA and PsA.<\/jats:p>","DOI":"10.3390\/ijms26052315","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:54:38Z","timestamp":1741154078000},"page":"2315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6833-0044","authenticated-orcid":false,"given":"Julie","family":"Sarrand","sequence":"first","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Baglione","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Bouvy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-1810","authenticated-orcid":false,"given":"Muhammad","family":"Soyfoo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, 1070 Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/kex345","article-title":"The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis","volume":"57","author":"Lim","year":"2018","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: A meta-analysis","volume":"18","author":"Landewe","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","article-title":"Prevalence of extra-articular manifestations in psoriatic arthritis: A systematic review and meta-analysis","volume":"59","author":"Pittam","year":"2020","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.46497\/ArchRheumatol.2024.10710","article-title":"Unmet needs in psoriatic arthritis, a narrative review","volume":"39","author":"Kalyoncu","year":"2024","journal-title":"Arch. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2018.1429918","article-title":"From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications","volume":"14","author":"Perrotta","year":"2018","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: Enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis--insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ni.3023","article-title":"Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage","volume":"15","author":"Sutherland","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","article-title":"Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Navarro-Compan, V., Puig, L., Vidal, S., Ramirez, J., Llamas-Velasco, M., Fernandez-Carballido, C., Almodovar, R., Pinto, J.A., Galindez-Aguirregoikoa, E., and Zarco, P. (2023). The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1332177"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: A novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: Structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0968-0004(03)00067-7","article-title":"The STIR-domain superfamily in signal transduction, development and immunity","volume":"28","author":"Novatchkova","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: Prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1037\/1076-8998.12.2.93","article-title":"The moderating role of employee positive well being on the relation between job satisfaction and job performance","volume":"12","author":"Wright","year":"2007","journal-title":"J. Occup. Health Psychol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/cr.2007.35","article-title":"A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses","volume":"17","author":"Chang","year":"2007","journal-title":"Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., and Guggino, G. (2021). Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637829"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-011-1006-5","article-title":"Structure and function of interleukin-17 family cytokines","volume":"2","author":"Zhang","year":"2011","journal-title":"Protein Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.smim.2007.10.007","article-title":"Th17 cells: Effector T cells with inflammatory properties","volume":"19","author":"Korn","year":"2007","journal-title":"Semin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-Dependent gamma\/delta T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cell.2015.08.058","article-title":"Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells","volume":"163","author":"Atarashi","year":"2015","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ge, Y., Huang, M., and Yao, Y.M. (2020). Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01558"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.coi.2008.09.004","article-title":"The IL-17 cytokine family and their role in allergic inflammation","volume":"20","author":"Wang","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: From bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.4049\/jimmunol.1200385","article-title":"IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation","volume":"188","author":"Griffin","year":"2012","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Monin, L., and Gaffen, S.L. (2018). Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028522"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sanchez-Rodriguez, G., and Puig, L. (2023). Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210305"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.21342","article-title":"Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis","volume":"52","author":"Koenders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/2772432817666220113112809","article-title":"Matrix Metalloproteinases; A Biomarker of Disease Activity and Prognosis in Spondyloarthritis: A Narrative Review","volume":"18","author":"Slouma","year":"2023","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Korkosz, M., Czepiel, M., Gula, Z., Stec, M., Weglarczyk, K., Rutkowska-Zapala, M., Gruca, A., Lenart, M., Baran, J., and Gasowski, J. (2018). Sera of patients with axial spondyloarthritis (axSpA) enhance osteoclastogenic potential of monocytes isolated from healthy individuals. BMC Musculoskelet. Disord., 19.","DOI":"10.1186\/s12891-018-2356-4"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis","volume":"14","author":"Taams","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/ard.55.4.268","article-title":"HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom","volume":"55","author":"Brown","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1038\/ncomms8146","article-title":"Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1","volume":"6","author":"Cortes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_52","first-page":"e919528","article-title":"RUNX3 Polymorphisms Affect the Risk of Ankylosing Spondylitis","volume":"26","author":"Liu","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tedeschi, V., Paldino, G., Alba, J., Molteni, E., Paladini, F., Scrivo, R., Congia, M., Cauli, A., Caccavale, R., and Paroli, M. (2023). ERAP1 and ERAP2 Haplotypes Influence Suboptimal HLA-B*27:05-Restricted Anti-Viral CD8+ T Cell Responses Cross-Reactive to Self-Epitopes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713335"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wellcome Trust Case Control Consortium, and The Australo-Anglo-American Spondylitis Consortium (TASC) (2007). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet., 39, 1329\u20131337.","DOI":"10.1038\/ng.2007.17"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e13190","DOI":"10.1111\/sji.13190","article-title":"Increased proportions of inflammatory T cells and their correlations with cytokines and clinical parameters in patients with ankylosing spondylitis from northern Sweden","volume":"96","author":"Lejon","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","article-title":"Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis","volume":"75","author":"Chen","year":"2012","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_58","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clim.2010.10.002","article-title":"Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis","volume":"138","author":"Zizzo","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3899\/jrheum.151133","article-title":"Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis","volume":"43","author":"Hayashi","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0950-3579(94)80018-9","article-title":"Psoriatic arthritis. Genetics and HLA antigens","volume":"8","author":"Eastmond","year":"1994","journal-title":"Baillieres Clin. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/jid.2012.456","article-title":"CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22","volume":"133","author":"Hijnen","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.4049\/jimmunol.1100427","article-title":"Cutting edge: Identification of a motile IL-17-producing gammadelta T cell population in the dermis","volume":"186","author":"Gray","year":"2011","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cei.12853","article-title":"Interleukin (IL)-9\/IL-9R axis drives gammadelta T cells activation in psoriatic arthritis patients","volume":"186","author":"Guggino","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.39261","article-title":"Brief report: Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_72","first-page":"369","article-title":"Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis","volume":"22","author":"Yoshiga","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.46497\/ArchRheumatol.2024.10050","article-title":"Secukinumab after first-line tumor necrosis factor-alpha inhibitor therapy in psoriatic arthritis: A real-world retrospective cohort study","volume":"39","author":"Ak","year":"2024","journal-title":"Arch. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: Results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/rheumatology\/keac522","article-title":"Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Adams, R., Maroof, A., Baker, T., Lawson, A.D.G., Oliver, R., Paveley, R., Rapecki, S., Shaw, S., Vajjah, P., and West, S. (2020). Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01894"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"Gensler","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: Results of two parallel phase 3 randomised controlled trials","volume":"82","author":"Deodhar","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_97","first-page":"23","article-title":"Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies","volume":"52","author":"Rudwaleit","year":"2025","journal-title":"J. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:30Z","timestamp":1760028450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":99,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26052315"],"URL":"https:\/\/doi.org\/10.3390\/ijms26052315","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}